Alsuma is owned by Meridian Medcl.
Alsuma contains Sumatriptan Succinate.
Alsuma has a total of 1 drug patent out of which 0 drug patents have expired.
Alsuma was authorised for market use on 29 June, 2010.
Alsuma is available in injectable;subcutaneous dosage forms.
Alsuma can be used as acute treatment of migraine attacks, with or without aura, and the treatment of cluster headache episodes.
The generics of Alsuma are possible to be released after 26 August, 2027.
|Patent Number||Company||Patent Title||Patent Expiry||Activity Alert|
|These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).|
|US7811254||MERIDIAN MEDCL||Autoinjector with needle depth adapter|| |
(4 years from now)
Market Authorisation Date: 29 June, 2010
Treatment: Acute treatment of migraine attacks, with or without aura, and the treatment of cluster headache episodes
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic